> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 4 Advisory Committees Renewed for 2 Years
- URL: https://www.fdaweb.com/4-advisory-committees-renewed-for-2-years/
- Published: 2022-06-08T12:00:00.000Z
- Updated: 2026-09-14T17:47:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152002

*Federal Register* notices: FDA has renewed the charters for four advisory committees for an additional two years. They are: 

- Drug Safety and Risk Management Advisory Committee’s new charter will be in effect until 5/31/2024 ([see notice](https://www.govinfo.gov/content/pkg/FR-2022-06-08/pdf/2022-12369.pdf?ref=fdaweb.com)).
- Peripheral and Central Nervous System Drugs Advisory Committee’s new charter will be in effect until 6/4/2024 ([see notice](https://www.govinfo.gov/content/pkg/FR-2022-06-08/pdf/2022-12368.pdf?ref=fdaweb.com)).
- Psychopharmacologic Drugs Advisory Committee’s new charter will be in effect until 6/4/2024 ([see notice](https://www.govinfo.gov/content/pkg/FR-2022-06-08/pdf/2022-12366.pdf?ref=fdaweb.com)).
- Pulmonary-Allergy Drugs Advisory Committee’s new charter will be in effect until 5/30/2024 ([see notice](https://www.govinfo.gov/content/pkg/FR-2022-06-08/pdf/2022-12370.pdf?ref=fdaweb.com)).